🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "major milestone" in the battle against superbug strains of the bacteria, according to health experts.

A Worldwide Public Health Issue

Cases of gonorrhoea are increasing around the world, with figures suggesting more than 82 million instances annually. Especially elevated rates are seen in the African continent and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have reached a all-time high, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely advancement in the face of rising global incidence, escalating drug resistance and the very limited treatment choices currently available.”

Public health authorities are particularly alarmed about the surge in treatment-resistant strains. The WHO has designated it as a "high-priority threat". Ongoing monitoring showed that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Drugs Gain Approval

Zoliflodacin, alternatively called a brand name, was approved by the US Food and Drug Administration in mid-December for use against gonorrhoea. This STI can lead to serious health problems, including infertility. Researchers anticipate that focused deployment of this new drug will help delay the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This treatment, which is additionally indicated for urinary tract infections, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin was the result of a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to bring it to fruition.

“This approval marks a huge turning point in the therapy of highly resistant gonorrhoea, which previously has been staying ahead of medical innovation.”

Clinical Trial Results and Worldwide Availability

According to data published in a major medical journal, zoliflodacin eradicated over nine in ten of genital gonorrhoea infections. This puts it on an equal footing with the typical regimen, which uses an injection and a pill. The study included nearly 1,000 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the rights to register and commercialise the drug in many developing nations.

Doctors treating patients have expressed positive views. The availability of a single-dose, oral treatment like this is seen as a "critical tool" for gonorrhoea control. This is considered vital to reduce the burden of the illness for people and to stop the proliferation of untreatable gonorrhoea around the world.